NCT04223895View on ClinicalTrials.gov

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

March 4, 2020

Study Completion Date

June 15, 2020

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

CKD-386 Formulation 1

A single oral dose of 1 tablet under fasting conditions for each period

DRUG

CKD-386 Formulation 2

A single oral dose of 1 tablet under fasting conditions for each period

DRUG

D012, D326 and D337

A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT04223895 - A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter